Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Working Capital Changes (2024 - 2025)

Historic Other Working Capital Changes for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$1.6 million.

  • Xilio Therapeutics' Other Working Capital Changes rose 3084.4% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year change of. This contributed to the annual value of $32.8 million for FY2024, which is 367080.61% up from last year.
  • Latest data reveals that Xilio Therapeutics reported Other Working Capital Changes of -$1.6 million as of Q3 2025, which was up 3084.4% from -$8.1 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Other Working Capital Changes ranged from a high of $46.2 million in Q1 2025 and a low of -$8.1 million during Q2 2025